高级检索
当前位置: 首页 > 详情页

Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Hepatology and Gastroenterologyand Department of Clinical Medicine, Aarhus UniversityHospital, Aarhus, Denmark [2]Department of Hepatology, Shenzhen Traditional ChineseMedicine Hospital, Shenzhen, Guangdong Province, China [3]Department of Gastroenterology and Hepatology, AalborgUniversity Hospital, Aalborg, Denmark [4]Department of Pediatrics and Adolescent Medicine, AarhusUniversity Hospital, Aalborg, Denmark [5]Steno Diabetes Center Aarhus, Aarhus University Hospital,Aarhus, Denmark [6]Department of Radiology, Aarhus University Hospital,Aarhus, Denmark [7]Department of Clinical Medicine, Health, Aarhus University,Aarhus, Denmark [8]Department of Endocrinology, Odense University Hospital,Odense, Denmark [9]Department of Clinical Research, Faculty of Health,University of Southern Denmark, Odense, Denmark
出处:
ISSN:

关键词: Children Obesity Metabolic-associated fatty liver disease Insulin-like growth factor axis Lifestyle intervention

摘要:
Obesity is a strong predictor for metabolic associated fatty liver disease (MAFLD), which has been associated with decreased insulin like growth factor 1 (IGF-1). In obesity, weight loss increases growth hormone secretion, but this is not unequivocally associated with increases in serum IGF-1 and IGF binding protein-3 (IGFBP-3). We studied the changes in the IGF axis in relation to weight loss and improvement in insulin resistance in children with or without MALFD after 10 weeks of lifestyle intervention at a weight loss camp (WLC). We investigated 113 (66 females) Caucasian children with obesity, median age 12.4 (range 7.3-14.6) years, before and after 10 weeks of lifestyle intervention at a WLC. We investigated children who was either MAFLD positive (n = 54) or negative (n = 59) before and after WLC. Children with MAFLD had lower baseline IGF-1 (249 ± 112 vs 278 ± 107 µg/l, P = 0.048), whereas the IGF-1/IGFBP-3 molar ratio was similar to children without MAFLD (19.4 ± 6.6 vs. 21.8 ± 6.6%, P = 0.108). When all children were considered as one group, WLC decreased SDS-BMI and HOMA-IR (P < 0.001, both) and increased IGF-1 (264 ± 110 vs 285 ± 108 µg/l, P < 0.001) and the IGF/IGFBP-3 molar ratio (20.7 ± 6.7 vs 22.4 ± 6.1%, P < 0.001). When categorized according to liver status, IGF-1 increased significantly in children with MAFLD (P = 0.008) and tended to increase in children without MAFLD (P = 0.052).   Conclusions: Ten weeks of lifestyle intervention decreased insulin resistance and improved the IGF axis. We observed slight differences in the IGF axis in relation to MAFLD status. This suggests that the IGF axis is primarily influenced by insulin resistance rather than MAFLD status. What is New: • Weight loss decreases insulin resistance and subsequently increases the IGF axis in children with obesity. • Children with MAFLD had an aberration in the IGF axis compared to their MAFLD negative counter parts and the IGF axis was primarily influenced by the decreased BMI-SDS and insulin resistance, rather than MAFLD status. What is Known: • NAFLD has previously been associated with reduced serum IGF-1 concentrations. • Data on the impact of MAFLD and aberrations in the growth hormone and IGF axis and the effects of lifestyle interventions in children are limited.© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 2 区 儿科
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 儿科
JCR分区:
出版当年[2021]版:
Q1 PEDIATRICS
最新[2023]版:
Q1 PEDIATRICS

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Hepatology and Gastroenterologyand Department of Clinical Medicine, Aarhus UniversityHospital, Aarhus, Denmark
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号